Takeuchi S, Saitoh H
Department of Urology, Saitama Medical Center of Saitama Medical School, Kawagoe, Japan.
Int J Urol. 1997 Jul;4(4):368-73. doi: 10.1111/j.1442-2042.1997.tb00210.x.
Candidate markers of prostatic metastases to bone, urinary deoxypyridinoline, serum carboxy-terminal propeptide of type 1 procollagen (P1CP), and pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen (1CTP), were measured to evaluate their prognostic efficacy.
Urinary levels (mean +/- SD) of deoxypyridinoline were measured by a competitive immunoassay, and serum levels of P1CP and 1CTP were measured by radioimmunoassay in 30 patients with benign prostatic hyperplasia, 18 patients with prostatic carcinoma without bone metastases, and 27 patients with prostatic carcinoma and bone metastases.
Urinary concentrations of deoxypyridinoline (pmol/micromol creatinine) in patients with prostatic carcinoma and bone metastases (10.4 +/- 7.7) were significantly higher than those in similar patients without bone metastases (4.3 +/- 1.3) and those in patients with benign prostatic hyperplasia (3.8 +/- 1.2). Serum levels of P1CP and 1CTP (ng/mL) in patients with prostatic carcinoma and bone metastases (262.6 +/- 188.7 and 10.3 +/- 9.5, respectively) were significantly higher than those in similar patients without bone metastases (118.1 +/- 30.2 and 4.3 +/- 1.4, respectively) and those in patients with benign prostatic hyperplasia (93.9 +/- 25.1 and 3.3 +/- 1.1, respectively). Serial measurements of urinary deoxypyridinoline and serum P1CP and 1CTP were correlated with a positive response to treatment (reduced measurements) and with the clinical progression of disease (increased measurements) before detection of new bone lesions by bone scintigram.
Urinary deoxypyridinoline, serum P1CP, and serum 1CTP should be useful markers in confirming and monitoring prostatic carcinoma metastases to bone.
检测尿脱氧吡啶啉、血清I型前胶原羧基端前肽（P1CP）和I型胶原吡啶啉交联羧基端肽（1CTP）这些前列腺骨转移潜在标志物，以评估其预后效能。
采用竞争性免疫分析法检测30例良性前列腺增生患者、18例无骨转移的前列腺癌患者和27例有骨转移的前列腺癌患者的尿脱氧吡啶啉水平（均值±标准差），采用放射免疫分析法检测血清P1CP和1CTP水平。
有骨转移的前列腺癌患者尿脱氧吡啶啉浓度（pmol/μmol肌酐）（10.4±7.7）显著高于无骨转移的类似患者（4.3±1.3）和良性前列腺增生患者（3.8±1.2）。有骨转移的前列腺癌患者血清P1CP和1CTP水平（ng/mL）（分别为262.6±188.7和10.3±9.5）显著高于无骨转移的类似患者（分别为118.1±30.2和4.3±1.4）和良性前列腺增生患者（分别为93.9±25.1和3.3±1.1）。在骨闪烁显像检测到新的骨病变之前，连续检测尿脱氧吡啶啉、血清P1CP和1CTP与治疗的阳性反应（测量值降低）和疾病的临床进展（测量值增加）相关。
尿脱氧吡啶啉、血清P1CP和血清1CTP应是确诊和监测前列腺癌骨转移的有用标志物。
